Prednisone

Generic Name: Prednisone

Brand Names: Deltasone, Rayos, Winpred

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₆O_₅

CAS Number: 53-03-2

Unique Ingredient Identifier: VB0R961HZT

Background: A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.

Prednisone was granted FDA approval on 21 February 1955.

Indication: Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.

Associated Conditions: Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis

Associated Therapies: Palliative Treatment

Clinical Trials

Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Phase 2

Completed

Conditions: Acute Lymphoblastic Leukemia
Lymphoblastic Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Dasatinib
Drug: Doxorubicin
Drug: Etoposide
Drug: Imatinib Mesylate
Other: Laboratory Biomarker Analysis
Drug: Prednisone
Biological: Rituximab
Drug: Vincristine Sulfate

First Posted Date: 2017-01-18

Last Posted Date: 2022-07-13

Lead Sponsor: University of Washington

Target Recruit Count: 54

Registration Number: NCT03023046

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

R-ACVBP and DA-EPOCH-R in Patients With Non-GCB DLBCL

Phase 3

Conditions: Lymphoma, Large B-Cell, Diffuse

Interventions: Drug: Rituximab
Drug: Etoposide
Drug: Doxorubicin
Drug: Vincristine
Drug: Cyclophosphamide
Drug: Vindesine
Drug: Bleomycin
Drug: Prednisone

First Posted Date: 2017-01-12

Last Posted Date: 2017-07-28

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 402

Registration Number: NCT03018626

Locations: 🇨🇳
Ru Feng, Guangzhou, Guangdong, China

Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer

Phase 4

Conditions: Castration-Resistant Prostatic Cancer
Stage IV Prostate Cancer
Hormone-Refractory Prostate Cancer
Recurrent Prostate Carcinoma
Metastatic Prostate Carcinoma

Interventions: Biological: GnRH agonist/antagonist
Drug: Enzalutamide
Drug: Prednisone
Drug: Abiraterone Acetate

First Posted Date: 2017-01-11

Last Posted Date: 2021-05-03

Lead Sponsor: Northwestern University

Target Recruit Count: 100

Registration Number: NCT03016741

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
University of Minnesota: Masonic Cancer Center, Minneapolis, Minnesota, United States

and more 1 locations

Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects

Phase 2

Active, not recruiting

Conditions: Prostate Cancer Metastatic Castration-Resistant
Metastatic Prostate Carcinoma
Abnormal DNA Repair
Stage IV Prostate Cancer

Interventions: Drug: Olaparib
Drug: Abiraterone Acetate
Drug: Prednisone

First Posted Date: 2017-01-06

Last Posted Date: 2023-08-30

Lead Sponsor: Northwestern University

Target Recruit Count: 70

Registration Number: NCT03012321

Locations: 🇺🇸
Weill Cornell Medical College, New York, New York, United States
🇺🇸
University of Virginia, Charlottesville, Virginia, United States
🇺🇸
Northwestern Medicine, Chicago, Illinois, United States

and more 15 locations

A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer

Phase 3

Active, not recruiting

Conditions: Prostate Cancer

Interventions: Drug: Apalutamide
Drug: LHRH Analogue
Drug: Abiraterone Acetate
Drug: Prednisone

First Posted Date: 2017-01-04

Last Posted Date: 2024-08-07

Lead Sponsor: Alliance Foundation Trials, LLC.

Target Recruit Count: 504

Registration Number: NCT03009981

Locations: 🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Atlantic Health System/Morristown Medical Center, Morristown, New Jersey, United States
🇺🇸
The Toledo Clinic, Toledo, Ohio, United States

and more 52 locations

Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT

Phase 2

Active, not recruiting

Conditions: Prostatic Neoplasms

Interventions: Drug: Pembrolizumab
Drug: SD-101
Drug: Leuprolide acetate
Drug: Abiraterone Acetate
Drug: Prednisone
Radiation: Stereotactic Body Radiation Therapy

First Posted Date: 2017-01-02

Last Posted Date: 2024-12-06

Lead Sponsor: David Oh

Target Recruit Count: 23

Registration Number: NCT03007732

Locations: 🇺🇸
University of California San Francisco, San Francisco, California, United States

A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma

Phase 2

Completed

Conditions: Lymphoma, Large B-Cell, Diffuse

Interventions: Drug: Durvalumab
Drug: Rituximab
Drug: Doxorubicin
Drug: Vincristine
Drug: Cyclophosphamide
Drug: Prednisone
Drug: Lenalidomide

First Posted Date: 2016-12-28

Last Posted Date: 2023-05-22

Lead Sponsor: Celgene

Target Recruit Count: 46

Registration Number: NCT03003520

Locations: 🇺🇸
Parkview Research Center, Fort Wayne, Indiana, United States
🇦🇹
Hanusch Krankenhaus, Wien, Austria
🇩🇰
Odense Universitetshospital, Odense C, Denmark

and more 17 locations

A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis

Phase 3

Completed

Conditions: ANCA-Associated Vasculitis

Interventions: Drug: Prednisone
Drug: Avacopan
Drug: Cyclophosphamide
Biological: Rituximab
Drug: Azathioprine

First Posted Date: 2016-12-16

Last Posted Date: 2024-01-29

Lead Sponsor: ChemoCentryx

Target Recruit Count: 331

Registration Number: NCT02994927

Locations: 🇬🇧
Clinical Trial Site, Westcliff-on-Sea, United Kingdom

The Novel Immunomodulatory and Anticoagulant Therapies for Recurrent Pregnancy Loss

Phase 4

Conditions: Recurrent Pregnancy Loss

Interventions: Drug: Aspirin
Drug: Dydrogesterone
Drug: Heparin
Drug: Prednisone
Drug: Immunoglobulin

First Posted Date: 2016-12-13

Last Posted Date: 2017-03-08

Lead Sponsor: Shanghai First Maternity and Infant Hospital

Target Recruit Count: 500

Registration Number: NCT02990403

Locations: 🇨🇳
Shanghai first Maternity and Infant health hospital, Tong Ji University, Shanghai, China

Chidamide Plus CHOEP Combined With Upfront ASCT in Untreated Peripheral T-cell Lymphoma

Phase 1

Conditions: T Cell Non-Hodgkin's Lymphoma

Interventions: Drug: Chidamide
Drug: Cyclophosphamide
Drug: Epirubicin
Drug: Vindesine
Drug: Etoposide
Drug: Prednisone

First Posted Date: 2016-12-08

Last Posted Date: 2016-12-08

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 100

Registration Number: NCT02987244

Locations: 🇨🇳
Peking Union medical college hospital, Beijing, Beijing, China
🇨🇳
Tianjin medical universty cancer institute & hospital, Tianjin, Tianjin, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy